by barry101 | Feb 13, 2025 | Press Releases
HOUSTON, Feb. 13, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it...
by barry101 | Feb 13, 2025 | Press Releases
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) in the first quarter of 2025 HOUSTON, Feb. 13, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...
by barry101 | Feb 11, 2025 | Press Releases
First of many site approvals, including sites in the US, Europe and the Middle East, expected throughout Q1-Q3 2025 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) in the first quarter of...
by barry101 | Jan 27, 2025 | Press Releases
– Walter Klemp, CEO of Moleculin, provides an update on the Company’s Phase 3 pivotal trial of Annamycin for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML) (the “MIRACLE” trial) – Watch...
by barry101 | Jan 8, 2025 | Press Releases
– Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) and engaged leading contract research organization (CRO); On track to begin dosing of Annamycin in combination with cytarabine...
